株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

インドの診断サービス市場の将来展望

Indian Diagnostic Services Market Outlook 2020

発行 RNCOS E-Services Pvt. Ltd. 商品コード 243950
出版日 ページ情報 英文 130 pages
即納可能
価格
本日の銀行送金レート: 1USD=111.43円で換算しております。
Back to Top
インドの診断サービス市場の将来展望 Indian Diagnostic Services Market Outlook 2020
出版日: 2016年05月01日 ページ情報: 英文 130 pages
概要

当レポートでは、インドの診断サービス市場について分析し、最新の市場構造・動向や、今後の市場動向見通し、部門別の詳細動向、今後の戦略展開の方向性、様々なビジネスモデル、消費者の認知度・行動、規制環境、主要企業のプロファイルなどを調査・考察しております。

第1章 アナリストの見解

第2章 分析手法

第3章 インド:マクロ経済指標および人口構成指標

  • 医療費
  • 医療インフラ
  • 巨大な人口ベース

第4章 市場のダイナミクス

  • 促進要因
  • 課題
  • 機会
  • 市場動向

第5章 疾病負荷

  • がん
  • 心血管疾患
  • 結核
  • マラリア
  • HIV/AIDS
  • 糖尿病
  • デング熱

第6章 診断サービス市場:現在・将来の分析

  • 病理学サービス
    • 市場見通し
    • 主要部門の分析
  • 放射線医学サービス
    • 市場見通し
    • 主要部門の分析

第7章 診断サービス市場:市場機会の評価

  • 診断試験所:都市部・農村部の分布状況
  • 検査のコスト評価:第一級・第二級都市の場合
    • 病理検査
    • 放射線検査
  • プライベート・エクイティ (PE) 投資の環境

第8章 診断サービス:ビジネスモデル

  • 官民連携 (PPP)
  • シングルスペシャルティ・モデル (SSM:特化領域型モデル)
  • ハブ・アンド・スポーク・モデル

第9章 第一級・第二級都市での消費者行動の研究

  • 第一級都市:診断検査への支出の急増
  • 医師が推薦する検査所の人気が最も高い
  • ブランドの人気:検査室の選好の主な決定要因
  • 独立系検査所:調査回答者の中では人気が高い
  • 民間検査施設の人気が、公営検査センターを上回る
  • 中規模検査所:調査回答者の現時点での選択

第10章 規制環境:認定と品質保証

  • 店舗・事業所法による要件
  • NABL (全国検査・測定施設認定委員会) の認定の権限
  • NABLの認定の過程
  • 診療所法(2010年)の想定されうる影響

第11章 競争環境 (事業概要、SWOT分析)

  • Super Religare Laboratories
  • Dr. Lal PathLabs
  • Metropolis Healthcare Limited
  • Thyrocare Technologies Limited
  • Quest Diagnostics India Private Limited,
  • PathCare Labs Pvt. Ltd.
  • Oncquest Laboratories Ltd.

図表一覧

目次

Diagnosis is the first step to disease management, as without accurate identification there is no possibility for accurate treatment. India is a land full of opportunities for players in the diagnostic service industry. The country has become one of the major destinations for various diagnostic services. Also, India's thriving economy is driving urbanization and developing an expanding middle class, with rising disposable incomes to spend on healthcare.

According to RNCOS' new research report “Indian Diagnostic Services Market Outlook 2020”, the diagnostic services market is expected to continue growing at 27.5% for next five years. This growth is likely to be driven by improving healthcare facilities, medical diagnostic and pathological laboratories, private-public projects, and the health insurance sector. Moreover, with the rise in health consciousness in the society and the rising burden of chronic diseases, this market will swell to approximately INR 860 Billion in revenues market by 2020.

Though a major portion of diagnostic business is being managed by the so called unorganized sector, the diagnostic service market is expected to become much more organized and consolidated with a lot of small and independent laboratory players becoming franchisees for the larger players. In order for clients and interested companies to enter this industry, our report provides an in-depth analysis of the cost assessment comparison of most common pathological and radiological tests among Tier I and Tier II cities.

RNCOS' present report provides an overview of the Indian diagnostic lab services market delivering an effective overview of the market size and future forecast. In terms of services, the market is dominated by pathology services, which account for approximately 70% of the market. The report additionally investigates the current market trends and opportunities with their impact on the performance of the sector. Further, the report provides consumer behavior patterns with respect to diagnostic services. Moreover, the report also provides insights regarding the prevalence and incidences of various diseases for which the diagnostic services are widely used.

The report also covers various business models in the Indian diagnostic services market, which generally scale up the level of diagnostic services and facilitate the entry of new market players. The report effectively assesses the implementation of commonly used models, such as PPP model, hub and spoke models, and even analyzes their impact in generating revenue. Moreover, RNCOS' industry experts prudently analyzed the regulatory and accreditation landscape with respect to setting up of diagnostic labs in Indian cities. The report, in this context, investigates into the viability of accrediting such diagnostics labs.

After an exhaustive study of the industry, the report presents a deep dive competitive landscape covering the top players along with business overview, strength-weakness analyses, recent developments, and growth strategies adopted by them to sustain their position in the Indian diagnostic services market.

Table of Contents

1. Analyst View

2. Research Methodology

3. India: Macro and Demographic Indicators

  • 3.1. Healthcare Spending
  • 3.2. Healthcare Infrastructure
  • 3.3. Huge Population Base

4. Market Dynamics

  • 4.1. Drivers
    • 4.1.1. Rising Demand of Preventive Care Diagnostics
    • 4.1.2. Rising Burden of Chronic Diseases
    • 4.1.3. Public - Private Partnership Models for Promoting Diagnostic Services
    • 4.1.4. Increasing Disposable Income
  • 4.2. Challenges
    • 4.2.1. Low Adoption of Advanced In-Vitro Diagnostic Technologies
    • 4.2.2. Lack of Proper Regulatory Framework
  • 4.3. Opportunities
    • 4.3.1. Increasing Investment by Foreign Companies
    • 4.3.2. Rise in Medical Tourism
    • 4.3.3. Tele-radiology: Prospective Service Facilitator for Remote Areas
    • 4.3.4. Emerging Tier II and Tier III cities
  • 4.4. Trends
    • 4.4.1. Increasing Automation Driving the Indian Diagnostic Services Market
    • 4.4.2. Inclination of Doctors towards Debt Financing
    • 4.4.3. Home Care Health Accessibility: Gaining Consumer Acceptance
    • 4.4.4. E-packages: New Way to Deliver Diagnostic Services
    • 4.4.5. Gene Based Testing Methods on the Rise

5. Disease Burden

  • 5.1. Cancer
  • 5.2. Cardiovascular Diseases
  • 5.3. Tuberculosis
  • 5.4. Malaria
  • 5.5. HIV/AIDS
  • 5.6. Diabetes Mellitus
  • 5.7. Dengue

6. Diagnostic Services Market: Current and Future Analysis

  • 6.1. Pathology Services
    • 6.1.1. Market Outlook
    • 6.1.2. Key Segment Analysis
  • 6.2. Radiology Services
    • 6.2.1. Market Outlook
    • 6.2.2. Key Segment Analysis

7. Diagnostic Services Market: Opportunity Assessment

  • 7.1. Diagnostics Laboratories: Urban and Rural Split
  • 7.2. Cost Assessment of Tests: Tier I and Tier II
    • 7.2.1. Pathological Tests
    • 7.2.2. Radiological Tests
  • 7.3. PE Investment Landscape

8. Diagnostic Services: Business Models

  • 8.1. Public Private Partnership (PPP)
    • 8.1.1. Understanding of Concept: Indian Scenario
    • 8.1.2. PPP Model in Healthcare and Diagnostic Services
    • 8.1.3. Key Healthcare and Diagnostics PPP Projects
    • 8.1.4. Case Study
  • 8.2. Single Specialty Model (SSM)
    • 8.2.1. Understanding the Concept: Indian Scenario
    • 8.2.2. Model's Key Advantages
    • 8.2.3. Case Study
  • 8.3. Hub and Spoke Model
    • 8.3.1. Understanding of Concept: Indian Scenario
    • 8.3.2. Model's Key Advantages
    • 8.3.3. Case Study

9. Consumer Behavior Research in Tier I and II

  • 9.1. Tier I: Spending Aggressively on Diagnostic Tests
  • 9.2. Physicians' Referred Labs Given Highest Preference
  • 9.3. Brand Popularity: Key Determinant for Lab Preference
  • 9.4. Independent Labs: Popular Among Respondents
  • 9.5. Private Lab Facilities Dominating Government Owned Centers
  • 9.6. Medium Scale Labs: Current Choice of the Respondents

10.Regulatory Environment: Accreditation and Quality Assurance

  • 10.1. Requirements for the Shop and Establishment Act
  • 10.2. NABL Accreditation Mandates
  • 10.3. NABL Accreditation Procedure
  • 10.4. Plausible Impact of the Clinical Establishments Act, 2010

11. Competitive Landscape (Business Overview, and Strength-Weakness Analysis)

  • 11.1. Super Religare Laboratories
  • 11.2. Dr. Lal PathLabs
  • 11.3. Metropolis Healthcare Limited
  • 11.4. Thyrocare Technologies Limited
  • 11.5. Quest Diagnostics India Private Limited,
  • 11.6. PathCare Labs Pvt. Ltd.
  • 11.7. Oncquest Laboratories Ltd.

List of Figures:

  • Figure 3-1: Healthcare Spending (US$ per head), 2015-2020
  • Figure 3-2: Consumer Healthcare Spending (Billion US$), 2015-2020
  • Figure 3-3: Share of Diagnostic Services in Total Healthcare Expenditure (%), 2015
  • Figure 3-4: Share of Public and Private Hospitals in Total Hospitals (%), 2015
  • Figure 3-5: Population (Million), 2015-2020
  • Figure 3-6: Population Breakup by Urban and Rural India (%), 2015
  • Figure 3-7: Middle Class Population (Million), 2015-2020
  • Figure 6-1: Share of Pathology and Radiology in Diagnostic Services Market (%), 2015
  • Figure 6-2: Share of Organized Diagnostic Services Market (%), 2015
  • Figure 6-3: Share of Organized Diagnostic Services Market (%), 2020
  • Figure 6-4: Diagnostic Services Market (Billion INR), 2015-2020
  • Figure 6-5: Pathology Services Market (Billion INR), 2015-2020
  • Figure 6-6: Share of Organized Pathology Services Market (%), 2020
  • Figure 6-7: Pathology Services Market by Segments (%), 2015
  • Figure 6-8: Radiology Services Market (Billion INR), 2015-2020
  • Figure 6-9: Share of Organized Radiology Services Market (%), 2020
  • Figure 6-10: Radiology Services Market by Segment (2015)
  • Figure 7-1: Percentage Breakup of Diagnostic Labs in Urban and Rural India
  • Figure 7-2: PE Investment in Key Sectors of Healthcare and Life Sciences (%), 2015
  • Figure 7-3: PE Investment (Million US$) and Number of Deals in Diagnostics, FY 2011-FY 2015
  • Figure 9-1: Tier-Wise Diagnostic Test Expenditure/Year
  • Figure 9-2: Consumer Preference for Physician Prescribed Lab
  • Figure 9-3: Factors Impacting Consumer Lab Preference
  • Figure 9-4: Consumer Preference by Lab Type (Independent/Hospital)
  • Figure 9-5: Consumer Preference by Lab Type (Government/Private)
  • Figure 9-6: Consumer Preference by Lab Type (Small/Medium/Large)
  • Figure 10-1: Flowchart for NABL Accreditation Procedure
  • Figure 11-1: Dr. Lal Path Labs - Breakup of Revenue by Region (%), 2015

List of Tables:

  • Table 3-1: Population Break-up by Age-Group (Million), 2015-2020
  • Table 5-1: Prevalence of Cancer (Million), 2013-2015
  • Table 5-2: Prevalence & Incidences of Tuberculosis (Million), 2013-2015
  • Table 5-3: Incidence of Malaria (Million), 2013-2015
  • Table 5-4: Prevalence of HIV/AIDS (Million), 2013-2015
  • Table 5-5: Prevalence of Diabetes (Million), 2013-2015
  • Table 5-6: Incidence of Dengue, 2013-2015
  • Table 7-1: Distribution of Diagnostic Labs in Urban Area (Class I to VI)
  • Table 7-2: Investigation Cost of Common Biochemical Tests in Tier I and Tier II (INR)
  • Table 7-3: Investigation Cost of Common Hematology Tests in Tier I and Tier II (INR)
  • Table 7-4: Investigation Cost of Common Immunology Tests in Tier I and Tier II (INR)
  • Table 7-5: Investigation Cost of Common Urinology Tests in Tier I and Tier II (INR)
  • Table 7-6: Investigation Cost of Common Coagulation Tests in Tier I and Tier II (INR)
  • Table 7-7: Investigation Cost of Common X-Ray Tests in Tier I and Tier II (INR)
  • Table 7-8: Investigation Cost of Common Ultrasound Tests in Tier I and Tier II (INR)
  • Table 7-9: Investigation Cost of Common MRI Tests in Tier I and Tier II (INR)
  • Table 7-10: Investigation Cost of Common CT Tests in Tier I and Tier II (INR)
  • Table 7-11: Investigation Cost of Common PET-CT Test in Tier I and Tier II (INR)
  • Table 8-1: Role of Key Stakeholders in Healthcare PPP Model
  • Table 8-2: Key Healthcare PPP Projects
  • Table 8-3: Key Diagnostic Services PPP Projects
  • Table 8-4: Advantages of Single Specialty Model in Diagnostic Services
  • Table 9-1: Characteristics of Sample Surveyed
  • Table 11-1: Dr. Lal Path Labs - Key Financials (Million INR), 2013-2015
  • Table 11-2: Quest Diagnostics - Key G2Financials (Million INR), 2013-2015
Back to Top